Research News & Publications

St. Jude finds NLRP12 as a new drug target for infection, inflammation and hemolytic diseases

06/01/2023

NLRP12 bridges hemolysis, inflammation and multi-organ damage. Learn how this ‘on’ switch for innate immune cell death could be a drug target to prevent pathology.
Genetic change increased bird flu severity during U.S. spread

05/30/2023

Find how H5N1 avian influenza viruses increased disease-causing abilities & gained the capability to enter mammalian brains as they spread west across North America.
SWI/SNF complexes “bookmark” cell identity during division

05/24/2023

Read about how Scientists at St. Jude determined how the SWI/SNF chromatin remodeling complex helps cancer cells remember how to be cancerous after division.
Epigenetic landscape modulates pioneer transcription factor binding

05/24/2023

St. Jude scientists are studying how pioneer transcription factors access tightly wound DNA. Learn about how their findings may impact therapeutic development.
Capturing transporter structure paves the way for drug development

05/23/2023

Learn how St. Jude scientists captured six new structures of the Spns2 transporter, providing insights to aid therapeutic design for cancer and other diseases.
St. Jude scientist M. Madan Babu elected to the Royal Society of London

05/10/2023

Director of the St. Jude Center of Excellence for Data-Driven Discovery named a fellow of the 360-year-old British scientific organization.
St. Jude tool gets more out of multi-omics data

05/04/2023

NetBID2 finds hidden drivers by extracting more from multi-omics data. Learn how the computational tool can find druggable targets in cancer and other diseases.
Study shines light on impact of environment on neurocognitive outcomes

04/28/2023

Find how the neighborhood economic hardship index predicts baseline and long-term outcomes in pediatric brain tumor patients treated with radiation therapy.
Clinical trial improves neurocognitive outcomes for childhood craniopharyngioma

04/18/2023

Proton therapy for craniopharyngioma had better neurocognitive than & similar survival outcomes as historical photon therapy. Read the phase 2 clinical trial.
Prime editing shows proof of concept for treating sickle cell disease

04/17/2023

Genomic prime editing, a new DNA-changing technology, fixed sickle cell disease mutations in patient cells. Learn how it could lead to cure for genetic anemias.